Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

A Vaccine (CVD908ssb-TXSVN) Trial for the Treatment of Patients with Multiple Myeloma, MAPSS Trial

Trial Status: administratively complete

This phase I/II trial tests the safety, side effects, and best dose and whether a cancer vaccine, called CVD908ssb-TXSVN, work to shrink tumors in patients with multiple myeloma. TXSVN is a weakened form of a live vaccine made from the Salmonella bacteria (Salmonella is a bacterial infection of the intestinal tract). It has been changed in the laboratory to produce a protein called Survivin , but at a lower dose than doses given to healthy volunteers. TXSVN may activate the immune system, which is the body's ability to fight disease, and help develop a response against cancer cells that express Survivin.